Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy
JAMA Cardiology
OCTOBER 1, 2024
This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of sudden cardiac death, hospitalization for heart failure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.
Let's personalize your content